Cellular and molecular regulation of inflammatory pain, nociception and hyperalgesia - The role of the transcription factor NF-κB as the lynchpin nocisensor: Hyperalgesic or analgesic effect?

Current Immunology Reviews

Volumn 3, Issue 2, 2007, Pages 117-131

  Haddad, John J ^a,b,c  

^a LEBANESE INTERNATIONAL UNIVERSITY   (Lebanon)

^b UNIVERSITY OF BALAMAND   (Lebanon)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Analgesia; Hyperalgesia; Inflammation; NF B; Nociception; Nocisensor; Pain; Transcription factors

Indexed keywords

ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID DERIVATIVE; ADVANCED GLYCATION END PRODUCT RECEPTOR; ANALGESIC AGENT; ARACHIDONIC ACID; BRADYKININ B1 RECEPTOR; BRADYKININ B2 RECEPTOR; DEXAMETHASONE; GALANIN RECEPTOR 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 1BETA; MELOXICAM; MITOGEN ACTIVATED PROTEIN KINASE; NITRIC OXIDE; OLIGODEOXYNUCLEOTIDE; PHOSPHOTRANSFERASE; PROSTAGLANDIN SYNTHASE; PROTEIN C FOS; PYRROLIDINE DITHIOCARBAMATE; ROFECOXIB; SALAZOSULFAPYRIDINE; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR REL; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR ALPHA; TUMOR SUPPRESSOR PROTEIN; ZINC FINGER PROTEIN;

ANALGESIC ACTIVITY; ANTIOXIDANT ACTIVITY; BIOSYNTHESIS; CHRONIC PAIN; CLINICAL TRIAL; CYLINDROMA; DISEASE SEVERITY; ELECTROACUPUNCTURE; ENZYME INHIBITION; FAMILIAL DISEASE; GENE EXPRESSION REGULATION; GENE REPRESSION; HUMAN; HYPERALGESIA; INFECTION; INFLAMMATION; INFLAMMATORY CELL; INTRACELLULAR TRANSPORT; MOLECULAR DYNAMICS; NEUROPATHIC PAIN; NOCICEPTION; NONHUMAN; OXIDATIVE STRESS; PAIN; PATHOGENESIS; PAW EDEMA; PRIORITY JOURNAL; PROTEIN DNA BINDING; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; TRAUMATOLOGY;

EID: 34249336067     PISSN: 15733955     EISSN: None     Source Type: Journal    
DOI: 10.2174/157339507780655504     Document Type: Review

References (171)

1. Haddad JJ. On the enigma of pain and hyperalgesia: A molecular perspective. Biochem Biophys Res Commun 2007; 353: 217-24.
2. Finnerup NB, Jensen TS. Mechanisms of disease: mechanism-based classification of neuropathic pain-a critical analysis. Nat Clin Pract Neurol 2006; 2: 107-15.
3. Garry EM, Jones E, Fleetwood-Walker SM. Nociception in vertebrates: key receptors participating in spinal mechanisms of chronic pain in animals. Brain Res Brain Res Rev 2004; 46: 216-24.
4. Basbaum AI, Jessell TM. The perception of pain. In: Principles of Neural Science, 4th Ed. McGraw-Hill Comp., Health Professions Division, USA. 2000; 473-91.
5. Saadé NE, Massaad CA, Kanaan SA, Safieh-Garabedian B, Jabbur SJ, Atweh SF. Pain and neurogenic inflammation: A neural substrate for neuroendocrine-immune interactions. In: Pain and Neuroimmune Interactions, Saadé NE, Apkarian AV and Jabbur SJ Ed. New York, Kluwer Academic/Plenum Publishers 2000; 111-23.
6. Block BM, Hurley RW, Raja SN. Mechanism-based therapies for pain. Drug News Perspect 2004; 17: 172-86.
7. Sung YJ, Ambron RT. Pathways that elicit long-term changes in gene expression in nociceptive neurons following nerve injury: contributions to neuropathic pain. Neurol Res 2004; 26: 195-203.
8. Chen F, Demers LM, Shi X. Upstream signal transduction of NF-κB activation. Curr Drug Targets Inflamm Allergy 2002; 1: 137-49.
9. Haddad JJ. Redox regulation of pro-inflammatory cytokines and IκB-α:/ NF-κB nuclear translocation and activation. Biochem Biophys Res Commun 2002; 296: 847-56.
10. Aggarwal BB. Nuclear factor-κB: The enemy within. Cancer Cell 2004; 6: 203-8.
11. Gilroy DW, Lawrence T, Perretti M, Rossi AG. Inflammatory resolution: new opportunities for drug discovery. Nat Rev Drug Discov 2004; 3: 401-16.
12. Isomura I, Morita A. Regulation of NF-κB signaling by decoy oligodeoxynucleotides. Microbiol Immunol 2006; 50: 559-63.
13. Nam NH. Naturally occurring NF-κB inhibitors. Mini Rev Med Chem 2006; 6: 945-51.
14. Park GY, Christman JW. Nuclear factor κB is a promising therapeutic target in inflammatory lung disease. Curr Drug Targets 2006; 7: 661-8.
15. Tegeder I, Niederberger E, Schmidt R, et al. Specific Inhibition of IκB kinase reduces hyperalgesia in inflammatory and neuropathic pain models in rats. J Neurosci 2004; 24: 1637-45.
16. Rittner HL, Brack A. Chemokines and pain. Curr Opin Investig Drugs 2006; 7: 643-6.
17. Zhang JH, Huang YG. The immune system: a new look at pain. Chin Mod J (Engl) 2006; 119: 930-8.
18. Fraser CC. Exploring the positive and negative consequences of NF-κB inhibition for the treatment of human disease. Cell Cycle 2006; 5: 1160-3.
19. Campbell KJ, Perkins ND. Regulation of NF-κB function. Biochem Soc Symp 2006; 73: 165-80.
20. Xiao G, Rabson AB, Young W, Qing G, Qu Z. Alternative pathways of NF-κB activation: a double-edged sword in health and disease. Cytokine Growth Factor Rev 2006; 17: 281-93.
21. Haddad JJ, Land SC. The differential expression of apoptosis factors in the alveolar epithelium is redox sensitive and requires NF-κB (RelA)-selective targeting. Biochem Biophys Res Commun 2000; 271: 257-67.
22. Anest V, Hanson JL, Cogswell PC, Steinbrecher KA, Strahl BD, Baldwin AS. A nucleosomal function for IκB kinase-α in NF-κB dependent gene expression. Nature 2003; 423: 659-63.
23. Hiscott J, Grandvaux N, Sharma S, Tenoever BR, Servant MJ, Lin R. Convergence of the NF-κB and interferon signaling pathways in the regulation of antiviral defense and apoptosis. Ann NY Acad Sci 2003; 1010: 237-48.
24. Lu T, Burdelya LG, Swiatkowski SM, et al. Secreted transforming growth factor-β2 activates NF-κB, blocks apoptosis, and is essential for the survival of some tumor cells. Proc Natl Acad Sci USA 2004; 101: 7112-7.
25. Takada Y, Singh S, Aggarwal BB. Identification of a p65 peptide that selectively inhibits NF-κB activation induced by various inflammatory stimuli and its role in down-regulation of NF-κB-mediated gene expression and up-regulation of apoptosis. J Biol Chem 2004; 279: 15096-104.
26. Haddad JJ. Redox and oxidant-mediated regulation of apoptosis signaling pathways: immuno-pharmaco-redox conception of oxidative siege versus cell death commitment. Int Immunopharmacol 2004; 4: 475-93.
27. Piva R, Belardo G, Santoro MG. NF-κB: a stress-regulated switch for cell survival. Antioxid Redox Signal 2006; 8: 478-86.
28. Taddeo B, Luo TR, Zhang W, Roizman B. Activation of NF-κB in cells productively infected with HSV-1 depends on activated protein kinase R and plays no apparent role in blocking apoptosis. Proc Natl Acad Sci USA 2003; 100: 12408-13.
29. Karin M, Greten FR. NF-κB: Linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 2005; 5: 749-59.
30. Karin M. NF-κB and cancer: mechanisms and targets. Mol Carcinog 2006; 45: 355-61.
31. Pikarsky E, Ben-Neriah Y. NF-κB inhibition: a double-edged sword in cancer? Eur J Cancer 2006; 42: 779-84.
32. Shishodia S, Aggarwal BB. Nuclear factor-κB activation mediates cellular transformation, proliferation, invasion angiogenesis and metastasis of cancer. Cancer Treat Res 2004; 119: 139-73.
33. Haddad JJ, Land SC. Nuclear factor-κB blockade attenuates but does not abrogate lipopolysaccharide-dependent tumor necrosis factor-α biosynthesis in alveolar epithelial cells. Biochem Biophys Res Commun 2001; 285: 267-72.
34. Haddad JJ, Olver RE, Land SC. Antioxidant/pro-oxidant equilibrium regulates HIF-1α and NF-κB redox sensitivity. Evidence for inhibition by glutathione oxidation in alveolar epithelial cells. J Biol Chem 2000; 275: 21130-9.
35. Bottero V, Withoff S, Verma IM. NF-κB and the regulation of hematopoiesis. Cell Death Differ 2006; 13: 785-97.
36. + blood monocytes and synovial tissue macrophages in rheumatoid arthritis. Arthritis Rheum 2004; 50: 1457-67.
37. Peng SL. Transcription factors in the pathogenesis of autoimmunity. Clin Immunol 2004; 110: 112-23.
38. Vermeulen L, Vanden Berghe W, Haegeman G. Regulation of NF-κB transcriptional activity. Cancer Treat Res 2006; 130: 89-102.
39. DiDonato JA, Hayakawa M, Rothwarf DM, Zandi E, Karin M. A cytokine-responsive IκB kinase that activates the transcription factor NF-κB. Nature 1997; 388: 548-54.
40. Chen LF, Greene WC. Shaping the nuclear action of NF-κB. Nat Rev Mol Cell Biol 2004; 5: 392-401.
41. Karin M, Yamamoto Y, Wang QM. The IKK NF-κB system: a treasure trove for drug development. Nat Rev Drug Discov 2004; 3: 17-26.
42. Yamamoto Y, Gaynor RB. IκB kinases: key regulators of the NF-κB pathway. Trends Biochem Sci 2004; 29: 72-9.
43. Haddad JJ, Land SC, Tarnow-Mordi WO, Zembala M, Kowalczyk D, Lauterbach R. Immunopharmacological potential of selective phosphodiesterase inhibition. II. Evidence for the involvement of an inhibitory-κB/ nuclear factor-κB-sensitive pathway in alveolar epithelial cells. J Pharmacol Exp Ther 2002; 300: 567-76.
44. Brennan P, O'Neill LA. 2-Mercaptoethanol restores the ability of nuclear factor-κB (NF-κB) to bind DNA in nuclear extracts from interleukin 1 -treated cells incubated with pyrollidine dithiocarbamate (PDTC). Evidence for oxidation of glutathione in the mechanism of inhibition of NF-κB by PDTC. Biochem J 1996; 320: 975-81.
45. Zandi E, Chen Y, Karin M. Direct phosphorylation of IκB by IKKα and IKKβ: discrimination between free and NF-κB bound substrate. Science 1998; 281: 1360-3.
46. Haddad JJ. Oxygen-sensitive pro-inflammatory cytokines, apoptosis signaling and redox-responsive transcription factors in development and pathophysiology. Cytokines Cell Mol Ther 2002; 7: 1-14.
47. Krakauer T. Molecular therapeutic targets in inflammation: cyclooxygenase and NF-κB. Curr Drug Targets Inflamm Allergy 2004; 3: 317-24.
48. Wajant H. TRAIL and NF-κB signaling: a complex relationship. Vitam Horm 2004; 67: 101-32.
49. Kanaan SA, Saadé NE, Haddad JJ, et al. Endotoxin-induced local inflammation and hyperalgesia in rats and mice: a new model for inflammatory pain. Pain 1996; 66: 373-9.
50. Wall PD. The mechanisms by which tissue damage and pain are related. In: Pain Mechanisms and Management, Ayrapetyan SN and Apkarian AV Ed, 1998; 252-9.
51. Woolf CJ. Dissecting out mechanisms responsible for peripheral neuropathic pain: implications for diagnosis and therapy. Life Sci 2004; 74:2605-10.
52. Woolf CJ. Pain: moving from symptom control toward mechanism-specific pharmacologic management. Ann Intern Med 2004; 140: 441-51.
53. Almeida TF, Roizenblatt S, Tufik S. Afferent pain pathways: a neuroanatomical review, Brain Res 2004; 1000: 40-56.
54. Baliki M, Al-Amin HA, Atweh SF, et al. Attenuation of neuropathic manifestations by local block of the activities of the ventro-lateral orbito-frontal area in the rat. Neuroscience 2003; 120: 1093-104.
55. Millan MJ, Kerkut GA, Zigmond MJ. The induction of pain: an integrative review. Prog Neurobiol 1999; 57: 1-164.
56. Dyck PJ, Mellinger JF, Ragan JJ, et al. Not indifference to pain but varieties of hereditary sensory and autonomic neuropathy. Brain 1983; 106: 373-90.
57. Loro PA, Burke WJ, Mcleod JG. Congenital sensory neuropathy with selective loss of small myelinated fibers. Ann Neurol 1978; 3: 179-82.
58. Cervero F, Laird JMA. One pain or many pains - A new look at pain mechanisms. News Physiologic Sci 1991; 6: 268-73.
59. Julius D, Basbaum AI. Molecular mechanisms of nociception. Nature 2001; 413: 203-10.
60. Saadé NE, Ibrahim MZ, Atweh SF, Jabbur SJ. Explosive autotomy induced by simultaneous dorsal column lesion and limb denervation: a possible model for acute deafferentation pain. Exp Neurol 1993; 119: 272-9.
61. Saadé NE, Shihabuddin LS, Atweh SF, Jabbur SJ. The role of previous nociceptive input in development of autotomy following cordotomy. Exp Neurol 1993; 119: 280-6.
62. Wall PD. Pain and animals. Nature 1985; 316: 672.
63. Wall PD. Inflammatory and neurogenic pain: new molecules, new mechanisms. Br J Anaesth 1995; 75: 123-4.
64. Zimmermann M, Herdegen T. Plasticity of the nervous system at the systemic, cellular and molecular levels: a mechanism of chronic pain and hyperalgesia. In: Progress in brain research. Carli G and Zimmermann M Ed, Amsterdam, Elsevier 1996; 233-59.
65. Dray A. Inflammatory mediators of pain. Br J Anaesth 1995; 75: 125-31.
66. Hunt SP. Pain control: breaking the circuit. Trends Physiologic Sci 2000; 21: 284-7.
67. Hunt SP, Mantyh PW. The molecular dynamics of pain control. Nat Neurosci 2001; 2: 83-91.
68. Hill RG. Molecular basis for the perception of pain. Neuroscientist 2001; 7: 282-92.
69. Poole S, Cunha FQ, Ferreira SH. Bradykinin, cytokines and inflammatory hyperalgesia. In: Pain and Neuroimmune Interactions. Saadé NE, Apkarian AV and Jabbur SJ Ed, New York, Kluwer Academic/Plenum Publishers 2000; 31-54.
70. Saadé NE, Massaad CA, Ochoa-Chaar CI, Jabbur SJ, Safieh-Garabedian B, Atweh SF. Upregulation of proinflammatory cytokines and nerve growth factor by intraplantar injection of capsaicin. J Physiol 2002; 545: 241-53.
71. Massaad CA, Safieh-Garabedian B, Poole S, Atweh SF, Jabbur SJ, Saadé NE. Involvement of substance P, CGRP and histamine in the hyperalgesia and cytokine upregulation induced by intraplantar injection of capsaicin in rats. J Neuroimmunol 2004; 153: 171-82.
72. Basbaum AI, Levine JD. The contribution of the nervous system to inflammation and inflammatory disease. Can J Physiol Pharmacol 1991; 69: 647-51.
73. Levine JD, Dardick SJ, Roizen MF, Helms C, Basbaum AI. Contribution of sensory afferents and sympathetic efferents to joint injury in experimental arthritis. J Neurosci 1986; 6: 3423-8.
74. Payan DG, Mcgillis JP, Renold FK, Mitsuhashi M, Goetzl EJ. Neuropeptide modulation of leukocyte function. Ann NY Acad Sci USA 1987; 496: 182-91.
75. Safieh-Garabedian B, Poole S, Haddad JJ, Massaad CA, Jabbur SJ, Saadé NE. The role of the sympathetic efferents in endotoxin-induced localized inflammatory hyperalgesia and cytokine upregulation. Neuropharmacology 2002; 42: 864-72.
76. Costa B, Trovato AE, Comelli F, Giagnoni G, Colleoni M. The non-psychoactive cannabis constituent cannabidiol is an orally effective therapeutic agent in rat chronic inflammatory and neuropathic pain. Eur J Pharmacol 2007; 556: 75-83.
77. Dray A. Tasting the inflammatory soup: The role of peripheral neurones. Pain Rev 1994; 1: 153-71.
78. McMahon SB, Koltzenburg M. The changing role of primary afferent neurons in pain. Pain 1990; 43: 269-72.
79. McMahon SB, Wall PD. Receptive fields of rat lamina 1 projection cells move to incorporate a nearby region of injury. Pain 1984; 19: 235-48.
80. Coderre TJ, Kats J, Vaccarino A, Melzack R. Contribution of central neuroplasticity to pathological pain: review of clinical and experimental evidence. Pain 1993; 52: 259-85.
81. Gracely RH, Lynch SA, Bennett GJ. Painful neuropathy: altered central processing maintained dynamically by peripheral input. Pain 1992; 51: 175-94.
82. Dib-Hajj SD, Fjell J, Cummins TR, et al. Plasticity of sodium channel expression in DRG neurons in the chronic constriction injury model of neuropathic pain. Pain 1999; 83: 591-600.
83. Devor M, Wall PD. Cross-excitation in dorsal root ganglia of nerve - injured and intact rats. J Neurophysiol 1990; 64: 1733-46.
84. Devor M, Seltzer Z. Pathophysiology of damaged nerve in relation to chronic pain. In: Textbook of Pain. Wall PD and Melzack R Ed, New York, Churchil Livingston 1999; 129-64.
85. Costa B, Siniscalco D, Trovato AE, et al. AM404, an inhibitor of anandamide uptake, prevents pain behavior and modulates cytokine and apoptotic pathways in a rat model of neuropathic pain. Br J Pharmacol 2006; 148: 1022-32.
86. Marchand F, Perretti M, McMahon SB. Role of the immune system in chronic pain. Nat Rev Neurosci 2005; 6: 521-32.
87. Bennett GJ. Does a neuroimmune interaction contribute to the genesis of painful peripheral neuropathies? Proc Natl Acad Sci USA 1999; 96: 7737-8.
88. Chacur M, Milligan ED, Gazda LS, et al. A new model of sciatic inflammatory neuritis (SIN): induction of unilateral and bilateral mechanical allodynia following acute unilateral peri-sciatic immune activation in rats. Pain 2001; 94: 231-44.
89. DeLeo JA, Colburn RW, Nichols ML, Malhotra A. Interleukin-6-mediated hyperalgesia/allodynia and increased spinal IL-6 expression in a rat mononeuropathy model. J Interferon Cytokine Res 1996; 16: 695-700.
90. Sommer C. Cytokines and neuropathic pain. In: Neuropathic Pain: Pathophysiology and Treatment, Hansson PT, Fields HL, Hill RG and Marchettini P Ed, Seattle, IASP Press 2001; 37-62.
91. Sommer C. Painful neuropathies. Curr Opin Neurol 2003 ; 16 : 623-8.
92. Saadé NE, Tabet MS, Banna NR, Atweh SF, Jabbur SJ. Inhibition of nociceptive evoked activity in spinal neurons through a dorsal column-brainstem-spinal loop. Brain Res 1985; 339: 115-8.
93. Saadé NE, Atweh SF, Jabbur SJ, Wall PD. Effects of lesions in the anterolateral columns and dorsolateral funiculi on self-mutilation behavior in rats. Pain 1990; 42: 313-21.
94. Kanaan SA, Safieh-Garabedian B, Haddad JJ, et al. Effects of various analgesic and anti-inflammatory drugs on endotoxin-induced hyperalgesia in rats and mice. Pharmacology 1997; 54: 285-97.
95. Jabbur SJ, Saadé NE. From electrical wiring to plastic neurons: evolving approaches to the study of pain. Pain 1999; 6: S87-92.
96. Saadé NE, Atweh SF, Bahuth NB, Jabbur SJ. Augmentation of nociceptive reflexes and chronic deafferentation pain by chemical lesions of either dopaminergic terminals or midbrain dopaminergic neurons. Brain Res 1997; 751: 1-12.
97. Saadé NE, Major SC, Jabbur SJ, Atweh SF, Kanaan SA, Safieh-Garabedian B. Involvement of capsaicin sensitive primary afferents in thymulin-induced hyperalgesia. J Neuroimmunol 1998; 91: 171-9.
98. 2 in endotoxin-induced localized inflammatory hyperalgesia. Br J Pharmacol 1997; 121: 1619-26.
99. Safieh-Garabedian B, Haddad JJ, Saadé NE. Cytokines in the central nervous system: Targets for therapeutic intervention. Curr Drug Targets CNS Neurol Disord 2004; 3: 271-80.
100. Lee KM, Kang BS, Lee HL, et al. Spinal NF-κB activation induces COX-2 upregulation and contributes to inflammatory pain hyper-sensitivity. Eur J Neurosci 2004; 19: 3375-81.
101. Liuzzo G, Santamaria M, Biasucci LM, et al. Persistent activation of nuclear factor κ-B signaling pathway in patients with unstable angina and elevated levels of C-reactive protein evidence for a direct proinflammatory effect of azide and lipopolysaccharide-free C-reactive protein on human monocytes via nuclear factor κ-B activation. J Am Coll Cardiol 2007; 49: 185-94.
102. Meffert MK, Baltimore D. Physiological functions for brain NF-κB. Trends Neurosci 2005; 28: 37-43.
103. Ichiyama T, Sakai T, Catania A, Barsh GS, Furukawa S, Lipton JM. Inhibition of peripheral NF-κB activation by central action of α-melanocyte-stimulating hormone. J Neuroimmunol 1999; 99: 211-7.
104. Nadjar A, Tridon V, May MJ, et al. NF-κB activates in vivo the synthesis of inducible Cox-2 in the brain. J Cereb Blood Flow Metab 2005; 25: 1047-59.
105. Wood JN. Regulation of NF-κB activity in rat dorsal root ganglia and PC12 cells by tumor necrosis factor and nerve growth factor. Neurosci Lett 1995; 192: 41-4.
106. Ma W, Bisby MA. Increased activation of nuclear factor-κB in rat lumbar dorsal root ganglion neurons following partial sciatic nerve injuries. Brain Res 1998; 797: 243-54.
107. Fernyhough P, Smith DR, Schapansky J, et al. Activation of nuclear factor-κB via endogenous tumor necrosis factor alpha regulates survival of axotomized adult sensory neurons. J Neurosci 2005; 25: 1682-90.
108. Igwe OJ. Modulation of peripheral inflammation in sensory ganglia by nuclear factor κB decoy oligodeoxynucleotide: involvement of SRC kinase pathway. Neurosci Lett 2005; 381: 114-9.
109. La Rosa G, Cardali S, Genovese T, et al. Inhibition of the nuclear factor-κB activation with pyrrolidine dithiocarbamate attenuating inflammation and oxidative stress after experimental spinal cord trauma in rats. J Neurosurg Spine 2004; 1: 311-21.
110. Yune TY, Lee SM, Kim SJ, et al. Manganese superoxide dismutase induced by TNF-β is regulated transcriptionally by NF-κB after spinal cord injury in rats. J Neurotrauma 2004; 21: 1778-94.
111. Brambilla R, Bracchi-Ricard V, Hu WH, et al. Inhibition of astroglial nuclear factor-κB reduces inflammation and improves functional recovery after spinal cord injury. J Exp Med 2005; 202: 145-56.
112. Ledeboer A, Gamanos M, Lai W, et al. Involvement of spinal cord nuclear factor-κB activation in rat models of proinflammatory cytokine-mediated pain facilitation. Eur J Neurosci 2005; 22: 1977-86.
113. Nakatani K, Yamakuni T, Kondo N, et al. γ-Mangostin inhibits inhibitor-κB kinase activity and decreases lipopolysaccharide-induced cyclooxygenase-2 gene expression in C6 rat glioma cells. Mol Pharmacol 2004; 66: 667-74.
114. Mitchell JA, Saunders M, Barnes PJ, Newton R, Belvisi MG. Sodium salicylate inhibits cyclo-oxygenase-2 activity independently of transcription factor (nuclear factor-κB) activation: role of arachidonic acid. Mol Pharmacol 1997; 51: 907-12.
115. Yin MJ, Yamamoto Y, Gaynor RB. The anti-inflammatory agents aspirin and salicylate inhibit the activity of IκB kinase-β. Nature 1998; 396: 77-80.
116. Vane JR, Botting RM. The mechanism of action of aspirin. Thromb Res 2003; 110: 255-8.
117. Broom DC, Samad TA, Kohno T, Tegeder I, Geisslinger G, Woolf CJ. Cyclooxygenase 2 expression in the spared nerve injury model of neuropathic pain. Neuroscience 2204; 124: 891-900.
118. Wu KK. Aspirin and other cyclooxygenase inhibitors: new therapeutic insights. Semin Vasc Med 2003; 3: 107-12.
119. Ferreira SH. Prostaglandins, pain, and inflammation. Agents Actions Suppl 1986; 19: 91-8.
120. Ma W, Eisenach JC. Cyclooxygenase 2 in infiltrating inflammatory cells in injured nerve is universally up-regulated following various types of peripheral nerve injury. Neuroscience 2003; 121: 691-704.
121. 2 synthesis in human neuroblastoma cells: involvement of p38 mitogen-activated protein kinase and nuclear factor-κB. J Neurochem 2000; 75: 2020-8.
122. Johnson-Pais TL, Singer FR, Bone HG, McMurray CT, Hansen MF, Leach RJ. Identification of a novel tandem duplication in exon 1 of the TNFRSF11A gene in two unrelated patients with familial expansile osteolysis. J Bone Miner Res 2003; 18: 376-80.
123. Valen G, Hansson GK, Dumitrescu A, Vaage J. Unstable angina activates myocardial heat shock protein 72, endothelial nitric oxide synthase, and transcription factors NF-κB and AP-1. Cardiovasc Res 2000; 47: 49-56.
124. Niederberger E, Tegeder I, Schafer C, Seegel M, Grosch S, Geisslinger G. Opposite effects of rofecoxib on nuclear factor-κB and activating protein-1 activation. J Pharmacol Exp Ther 2003; 304: 1153-60.
125. Niederberger E, Manderscheid C, Grosch S, Schmidt H, Ehnert C, Geisslinger G. Effects of the selective COX-2 inhibitors celecoxib and rofecoxib on human vascular cells. Biochem Pharmacol 2004; 68: 341-50.
126. Koppert W, Wehrfritz A, Korber N, et al. The cyclooxygenase isozyme inhibitors parecoxib and paracetamol reduce central hyperalgesia in humans. Pain 2004; 108: 148-53.
127. Lai J, Ossipov MH, Vanderah TW, Malan TP Jr, Porreca F. Neuropathic pain: the paradox of dynorphin. Mol Interv 119; 1: 160-7.
128. Bakalkin G, Yakovleva T, Terenius L. Prodynorphin gene expression relates to NF-κB factors. Brain Res Mol Brain Res 1994; 24: 301-12.
129. Brummelkamp TR, Nijman SM, Dirac AM, Bernards R. Loss of the cylindromatosis tumor suppressor inhibits apoptosis by activating NF-κB. Nature 2003; 424: 797-801
130. Oosterkamp HM, Neering H, Nijman SM, et al. An evaluation of the efficacy of topical application of salicylic acid for the treatment of familial cylindromatosis. Br J Dermatol 2006; 155: 182-5.
131. Sommer C, Kress M. Recent findings on how proinflammatory cytokines cause pain: Peripheral mechanisms in inflammatory and neuropathic hyperalgesia. Neurosci Lett 2004; 361: 184-7.
132. DeLeo JA, Tanga FY, Tawfik VL. Neuroimmune activation and neuroinflammation in chronic pain and opioid tolerance/hyperalgesia. Neuroscientist 1996; 10: 40-52.
133. Laughlin TM, Bethea JR, Yezierski RP, Wilcox GL. Cytokine involvement in dynorphin-induced allodynia. Pain 2000; 84: 159-67.
134. Friedman R. Pain at the cellular level: the role of the cytokine tumor necrosis factor-α. Reg Anesth Pain Med 2000; 25: 110-2.
135. Ritchie ME. Nuclear factor-κB is selectively and markedly activated in humans with unstable angina pectoris. Circulation 1998; 98: 1707-13.
136. Jenkins N. Activation of nuclear factor-κB in unstable angina. Circulation 1999; 100: 1462-3.
137. Smith RS, Harris SG, Phipps R, Iglewski B. The Pseudomonas aeruginosa quorum-sensing molecule N-(3-oxododecanoyl)homoserine lactone contributes to virulence and induces inflammation in vivo. J Bacteriol 2002; 184: 1132-9.
138. Zelenka M, Schafers M, Sommer C. Intraneural injection of interleukin-1β and tumor necrosis factor-α into rat sciatic nerve at physiological doses induces signs of neuropathic pain. Pain 2005; 116: 257-63.
139. Mogil JS, McCarson KE. Identifying pain genes: bottom-up and top-down approaches. J Pain 2000; 1: 66-80.
140. Lorimer DD, Matkowskj K, Benya RV. Cloning, chromosomal location, and transcriptional regulation of the human galanin-1 receptor gene (GALN1R). Biochem Biophys Res Commun 1997; 241: 558-64.
141. Dray A. Kinins and their receptors in hyperalgesia. Can J Physiol Pharmacol 1997; 75: 704-12.
142. Calixto JB, Medeiros R, Fernandes ES, Ferreira J, Cabrini DA, Campos MM. Kinin B1 receptors: key G-protein-coupled receptors and their role in inflammatory and painful processes. Br J Pharmacol 2004; 143: 803-18.
143. Marceau F, Regoli D. Bradykinin receptor ligands: therapeutic perspectives. Nat Rev Drug Discov 2004; 3: 845-52.
144. Ueno A, Oh-ishi S. Roles for the kallikrein-kinin system in inflammatory exudation and pain: lessons from studies on kininogen-deficient rats. J Pharmacol Sci 2003; 93: 1-20.
145. 1 receptor expression by endogenous glucocorticoids hormones in rats. Br J Pharmacol 2001; 132: 567-77.
146. 2-evoked regulation of HIF-1α and NF-κB in perinatal lung epithelium requires glutathione biosynthesis. Am J Physiol Lung Cell Mol Physiol. 2000; 278: L492-503.
147. Chan CF, Sun WZ, Lin JK, Lin-Shiau SY. Activation of transcription factors of nuclear factor-κB, activator protein-1 and octamer factors in hyperalgesia. Eur J Pharmacol 2000; 402: 61-8.
148. Inoue G, Ochiai N, Ohtori S, et al. Injection of nuclear factor-κB decoy into the sciatic nerve suppresses mechanical allodynia and thermal hyperalgesia in a rat inflammatory pain model. Spine 2006; 31: 2904-8.
149. Sun T, Song WG, Fu ZJ, Liu ZH, Liu YM, Yao SL. Alleviation of neuropathic pain by intrathecal injection of antisense oligonucleotides to p65 subunit of NF-κB. Br J Anaesth 2006; 97: 553-8.
150. Sakaue G, Shimaoka M, Fukuoka T, et al. NF-κB decoy suppresses cytokine expression and thermal hyperalgesia in a rat neuropathic pain model. Neuroreport 2001; 12: 2079-84.
151. Jun-Ichi S, Hiroshi I, Ryo G, Ryuichi M, Kensuke E, Mitsuaki I. Initial clinical cases of the use of a NF-κB decoy at the site of coronary stenting for the prevention of restenosis. Circ J 2004; 68: 270-1.
152. Alam SE, Nasser SS, Fernainy KE, Habib AA, Badr KF. Cytokine imbalance in acute coronary syndrome. Curr Opin Pharmacol 204; 4: 166-70.
153. Rothwarf DM, Zandi E, Natoli G, Karin M. IKK-γ is an essential regulatory subunit of the IκB kinase complex. Nature 1998; 395: 297-300.
154. Yu CG, Yezierski RP. Activation of the ERK1/2 signaling cascade by excitotoxic spinal cord injury. Brain Res Mol Brain Res 2005; 138: 244-55.
155. Liu YL, Zhou LJ, Hu NW, et al. Tumor necrosis factor-α induces long-term potentiation of C-fiber evoked field potentials in spinal dorsal horn in rats with nerve injury: The role of NF-κB, JNK and p38 MAPK. Neuropharmacology 2007; 52: 708-15.
156. Park HJ, Lee HS, Lee HJ, et al. Decrease of the electroacupuncture-induced analgesic effects in nuclear factor-κB1 knockout mice. Neurosci Lett 2002; 319: 141-4.
157. Borner C, Hollt V, Kraus J. Involvement of activator protein-1 in transcriptional regulation of the human μ-opioid receptor gene. Mol Pharmacol 2002; 61: 800-5.
158. Kraus J, Borner C, Giannini E, Hollt V. The role of NF-κB in tumor necrosis factor-regulated transcription of the human μ-opioid receptor gene. Mol Pharmacol 2003; 64: 876-84.
159. Chen YL, Law PY, Loh HH. Action of NF-κB on the delta opioid receptor gene promoter. Biochem Biophys Res Commun 2007; 352: 818-22.
160. Bierhaus A, Haslbeck KM, Humpert PM, et al. Loss of pain perception in diabetes is dependent on a receptor of the immunoglobulin superfamily. J Clin Invest 2004; 114: 1741-51.
161. Kim IT, Park HJ, Nam JH, et al. In vitro and in vivo anti-inflammatory and antinociceptive effects of the methanol extract of the roots of Morinda officinalis. J Pharm Pharmacol 2005; 57: 607-15.
162. Wang S, Lim G, Yang L, Sung B, Mao J. Downregulation of spinal glutamate transporter EAAC1 following nerve injury is regulated by central glucocorticoid receptors in rats. Pain 2006; 120: 78-85.
163. Hermoso MA, Cidlowski JA. Putting the brake on inflammatory responses: the role of glucocorticoids. IUBMB Life 2003; 55: 497-504.
164. Wu LC, Goettl VM, Madiai F, Hackshaw KV, Hussain SR. Reciprocal regulation of nuclear factor κB and its inhibitor ZAS3 after peripheral nerve injury. BMC Neurosci 2006; 7: 4.
165. Xie W, Luo S, Xuan H, et al. Betamethasone affects cerebral expressions of NF-κB and cytokines that correlate with pain behavior in a rat model of neuropathy. Ann Clin Lab Sci 2006; 36: 39-46.
166. Frassdorf J, Weber NC, Obal D, et al. Morphine induces late cardioprotection in rat hearts in vivo: the involvement of opioid receptors and nuclear transcription factor κB. Anesth Analg 2005; 101: 934-41.
167. Haddad JJ. Cytokines and related receptor-mediated signaling pathways. Biochem Biophys Res Commun 2002; 297: 700-13.
168. Haddad JJ. On the antioxidant mechanisms of Bcl-2: a retrospective of NF-κB signaling and oxidative stress. Biochem Biophys Res Commun 2004; 322: 355-63.
169. Haddad JJ, Harb HL. L-γ-Glutamyl-L-cysteinyl-glycine (glutathione; GSH) and GSH-related enzymes in the regulation of pro- and anti-inflammatory cytokines: a signaling transcriptional scenario for redox(y) immunologic sensor(s)? Mol Immunol 2005; 42: 987-1014.
170. 193-195 receptor antagonism in the alveolar epithelium. Biochem J 2001; 355: 29-38.
171. D'Acquisto F, May MJ, Ghosh S. Inhibition of nuclear factor-κB (NF-κB): an emerging theme in anti-inflammatory therapies. Mol Intervent 2002; 2: 22-35.